Gilead Sciences, Inc. (GILD) Earns Hold Rating from Jefferies Group LLC
Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “hold” rating reaffirmed by analysts at Jefferies Group LLC in a research report issued on Wednesday, MarketBeat.com reports. They currently have a $93.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price points to a potential upside of 12.84% from the stock’s previous close.
Several other equities analysts have also weighed in on GILD. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Mizuho restated a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Deutsche Bank AG restated a “buy” rating and set a $81.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Leerink Swann restated a “hold” rating and set a $74.00 price target on shares of Gilead Sciences in a report on Tuesday, July 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of Gilead Sciences in a research note on Thursday, July 27th. Eleven research analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $85.36.
Shares of Gilead Sciences (NASDAQ GILD) traded down 0.93% on Wednesday, hitting $82.42. The company had a trading volume of 6,704,083 shares. The company has a 50 day moving average of $80.13 and a 200-day moving average of $71.40. The company has a market cap of $107.63 billion, a price-to-earnings ratio of 8.95 and a beta of 1.14. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s revenue was down 8.2% on a year-over-year basis. During the same period in the previous year, the firm posted $3.08 earnings per share. On average, analysts forecast that Gilead Sciences will post $8.78 earnings per share for the current year.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now directly owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. Insiders sold a total of 388,486 shares of company stock worth $31,178,297 in the last 90 days. Company insiders own 1.30% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Waldron LP grew its stake in Gilead Sciences by 20.4% in the first quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock valued at $711,000 after purchasing an additional 1,752 shares in the last quarter. NBT Bank N A NY increased its position in shares of Gilead Sciences by 203.8% during the 1st quarter. NBT Bank N A NY now owns 41,272 shares of the biopharmaceutical company’s stock worth $2,804,000 after purchasing an additional 27,685 shares during the last quarter. Mycio Wealth Partners LLC increased its position in shares of Gilead Sciences by 13.0% during the 1st quarter. Mycio Wealth Partners LLC now owns 10,146 shares of the biopharmaceutical company’s stock worth $689,000 after purchasing an additional 1,165 shares during the last quarter. Cubic Asset Management LLC increased its position in shares of Gilead Sciences by 1.9% during the 1st quarter. Cubic Asset Management LLC now owns 29,701 shares of the biopharmaceutical company’s stock worth $2,017,000 after purchasing an additional 560 shares during the last quarter. Finally, Dubuque Bank & Trust Co. increased its position in shares of Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 267 shares during the last quarter. Institutional investors own 73.99% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.